Adenylosuccinic acid: a novel inducer of the cytoprotectant Nrf2 with efficacy in Duchenne muscular dystrophy.
Emma RybalkaCraig A GoodmanDean G CampeljAlan HayesCara A TimpaniPublished in: Current medical research and opinion (2021)
Adenylosuccinic acid (ASA) modifies Duchenne muscular dystrophy (DMD) progression in dystrophic mdx mice and human DMD patients. Despite an established role for ASA in augmenting metabolism and cellular energy homeostasis, our previous data suggests an undiscovered ulterior mode of action capable of modifying DMD disease course. Here, we identify ASA as a novel inducer of nuclear factor erythroid 2-related factor-2 (Nrf2), master regulator of the antioxidant and cytoprotective response to cell stress.
Keyphrases
- duchenne muscular dystrophy
- nuclear factor
- oxidative stress
- end stage renal disease
- muscular dystrophy
- toll like receptor
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- single cell
- prognostic factors
- type diabetes
- stem cells
- peritoneal dialysis
- electronic health record
- immune response
- big data
- cell therapy
- machine learning
- patient reported outcomes
- skeletal muscle
- deep learning
- stress induced
- high fat diet induced
- inflammatory response
- wild type